Complement activation and coagulopathy - an ominous duo in COVID19

References

• Drosten C, Günther S, Preiser W, et al. Identification of a novel corona virus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976.
   PubMed Web of Science ®Google Scholar
• Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535–538.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Huang HJ, Zhuang DL, et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and auto dock simulation of ACE2. Infect Dis Poverty. 2020;9(1). DOI:10.1186/s40249-020-00691-6.
   Web of Science ®Google Scholar
• Meo SA, Alhowikan AM, Al-khlaiwi T, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012–2019.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.
   PubMed Web of Science ®Google Scholar
• Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474.
   PubMed Web of Science ®Google Scholar
• Sarma VJ, Huber-Lang M, Ward PA. Complement in lung disease. Autoimmunity. 2006;39(5):387–394.
   PubMed Web of Science ®Google Scholar
• Bera MM, Lu B, Martin TR, et al. Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins. J Immunol. 2011;187(8):4245–4255.
   PubMed Web of Science ®Google Scholar
• Wang R, Xiao H, Guo R. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015;4(5):e28–e28.
   PubMed Web of Science ®Google Scholar
• Ramlall V, Thangaraj P, Meydan C, et al. Identification of immune complement function as a determinant of adverse SARS-CoV-2 infection outcome 2020.. medRxiv. 2020;05:05.20092452.
   Google Scholar
• Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9(5):e01753–18.
   PubMed Web of Science ®Google Scholar
• Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Translational Research. 2020. doi: 10.1016/j.trsl.2020.04.007
   Google Scholar
• Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID‐19 coagulopathy in caucasian patients. Br J Haematol. 2020;189(6):1044–1049.
   PubMed Web of Science ®Google Scholar
• Merle NS, Church SE, Fremeaux-Bacchi V, et al. Complement system part I – molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
   PubMed Web of Science ®Google Scholar
• Galvan MD, Greenlee-Wacker MC, Bohlson SS. C1q and phagocytosis: the perfect complement to a good meal. J Leukoc Biol. 2012;92(3):489–497.
   PubMed Web of Science ®Google Scholar
• Oikonomopoulou K, Ricklin D, Ward PA, et al. Interactions between coagulation and complement—their role in inflammation. Semin Immunopathol. 2011;34(1):151–165.
   PubMed Web of Science ®Google Scholar
• Iwanaga S, Lee BL. Recent advances in the innate immunity of invertebrate animals. J Biochem Mol Biol. 2005;38(2):128–150.
   PubMedGoogle Scholar
• Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–432.
   PubMed Web of Science ®Google Scholar
• Ip WKE, Chan KH, Law HKW, et al. Mannose‐binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis. 2005;191(10):1697–1704.
   PubMed Web of Science ®Google Scholar
• Leth-Larsen R, Zhong F, Chow VTK, et al. The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages. Immunobiology. 2007;212(3):201–211.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao G, Song N, et al. Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):1–12.
   Google Scholar
• Jiang Y, Li J, Teng Y, et al. Complement receptor C5aR1 inhibition reduces pyroptosis in hDPP4-transgenic mice infected with MERS-CoV. Viruses. 2019;11(1):39.
   Web of Science ®Google Scholar
• Sanchez-Galan E, Gomez-Hernandez A, Vidal C, et al. Leukotriene B4 enhances the activity of nuclear factor- B pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res. 2008;81(1):216–225.
   PubMed Web of Science ®Google Scholar
• Yang M, Hon KL, Li K, et al. The effect of SARS coronavirus on blood system: its clinical findings and the pathophysiologic hypothesis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003;11(3):217‐21.
   Google Scholar
• Xiang-hua Y, Wang L, Liang A, et al. Severe acute respiratory syndrome and venous thromboembolism in multiple organs. Am J Respir Crit Care Med. 2010;182(3):436–437.
   PubMed Web of Science ®Google Scholar
• Umapathi T, Kor AC, Venketasubramanian N, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004;251(10):1227–1231.
   PubMed Web of Science ®Google Scholar
• Ng WF, Wong SF, Lam A, et al. The placentas of patients with severe acute respiratory syndrome: a pathophysiological evaluation. Pathology. 2006;38(3):210–218.
   PubMed Web of Science ®Google Scholar
• Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2014;235(2):185–195.
   Web of Science ®Google Scholar
• Ng LF, Hibberd ML, Ooi -E-E, et al. A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. BMC Infect Dis. 2004;4(1). DOI:10.1186/1471-2334-4-34.
   PubMedGoogle Scholar
• Algaissi A, Agrawal AS, Han S, et al. Elevated human dipeptidyl peptidase 4 expression reduces the susceptibility of hDPP4 transgenic mice to middle east respiratory syndrome coronavirus infection and disease. J Infect Dis. 2019;219(5):829–835.
   PubMed Web of Science ®Google Scholar
• Hwang SM, Na BJ, Jung Y, et al. Clinical and laboratory findings of middle east respiratory syndrome coronavirus infection. Jpn J Infect Dis. 2019;72(3):160–167.
   PubMed Web of Science ®Google Scholar
• Al-Abdallat MM, Payne DC, Alqasrawi S, et al. Hospital-associated outbreak of middle east respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clinl Infect Dis. 2014;59(9):1225–1233.
   PubMed Web of Science ®Google Scholar
• Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752–761.
   PubMed Web of Science ®Google Scholar
• Algahtani H, Subahi A, Shirah B Neurological complications of middle east respiratory syndrome coronavirus: a report of two cases and review of the literature. Case Reports in Neurological Medicine, 1–6 (2016).
   Google Scholar
• Yang W, Punyadarsaniya D, Lambertz RLO, et al. Mutations during the adaptation of H9N2 avian influenza virus to the respiratory epithelium of pigs enhance sialic acid binding activity and virulence in mice. J Virol. 2017;91(8):e02125–16. 2017.
   PubMed Web of Science ®Google Scholar
• Munster VJ, Koopmans M, Doremalen NV, et al. A novel coronavirus emerging in China — key questions for impact assessment. N Engl J Med. 2020;382(8):692–694. 2020.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Viceconte G, Ergonul O, et al. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729–734.
   PubMed Web of Science ®Google Scholar
• Kwong KCNK, Mehta PR, Shukla G, et al. COVID-19 SARS and MERS: a neurological perspective. J Clinic Neurosci. 2020;77:13–16.
   PubMed Web of Science ®Google Scholar
• Casas CG, Català A, Hernández GC, et al. Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;Vol 183(1):71–77.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Korompoki E, Fotiou D, et al. Organ-specific manifestations of COVID-19 infection [published online ahead of print, 2020 Jul 27]. Clin Exp Med. 2020;20(1):1–14.
   PubMedGoogle Scholar
• Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834–847.
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. [2020 Apr 30]. 2020;382:(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.
   PubMed Web of Science ®Google Scholar
• Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061.
   PubMed Web of Science ®Google Scholar
• Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099.
   PubMed Web of Science ®Google Scholar
• Iba T, Levy JH, Levi M, et al. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020;48(9):1358–1364.
   PubMed Web of Science ®Google Scholar
• Marongiu F, Grandone E, Barcellona D. Pulmonary thrombosis in 2019-nCoV pneumonia? J Thromb Haemost. 2020;18(6):1511–1513.
   PubMed Web of Science ®Google Scholar
• Spiezia L, Boscolo A, Poletto F, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998–1000.
   PubMed Web of Science ®Google Scholar
• Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020;133(11):1261–1267.
   PubMed Web of Science ®Google Scholar
• Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020;18(6):1517–1519.
   PubMed Web of Science ®Google Scholar
• Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14.
   PubMed Web of Science ®Google Scholar
• Lu YF, Pan LY, Zhang WW, et al. A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int J Infect Dis. 2020;100:34–41.
   PubMed Web of Science ®Google Scholar
• Mei F, Fan J, Yuan J, et al. Comparison of venous thromboembolism risks between COVID-19 pneumonia and community-acquired pneumonia patients. Arterioscler Thromb Vasc Biol. 2020;40(9):2332–2337.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489–500.
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 2020;191: 145–147.
   PubMed Web of Science ®Google Scholar
• Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738–1742.
   PubMed Web of Science ®Google Scholar
• Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation. 2020;141(22):1739–1741.
   PubMed Web of Science ®Google Scholar
• Iba T, Levy JH, Connors JM, et al. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360.
   PubMed Web of Science ®Google Scholar
• Yang M, Ng MH, Li CK, et al. Thrombopoietin levels increased in patients with severe acute respiratory syndrome. Thromb Res. 2008;122(4):473–477.
   PubMed Web of Science ®Google Scholar
• Gralinski LE, Bankhead A3, Jeng S, et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio. 2013;4(4):e00271–13.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cao W, Xiao M, et al. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Zhonghuaxue Ye Xue Za Zhi. 2020;41:E006.
   PubMedGoogle Scholar
• Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):E575–E582.
   PubMed Web of Science ®Google Scholar
• Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11(4):761–767.
   Google Scholar
• Liao S, Woulfe T, Hyder S, et al. Incidence of venous thromboembolism in different ethnic groups: a regional direct comparison study. J Thromb Haemost. 2014;12(2):214–219.
   PubMed Web of Science ®Google Scholar
• White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res. 2009;123:S11–7.
   PubMed Web of Science ®Google Scholar
• Gallus A, Jindal R, Wang C, et al. Incidence of venous thromboembolism in Asian populations: a systematic review. Thromb Haemost. 2017;117(12):2243–2260.
   PubMed Web of Science ®Google Scholar
• Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clinic Chem Lab Med. 2020;58(7):1116–1120.
   PubMed Web of Science ®Google Scholar
• Di Micco P, Russo V, Carannante N, et al. Clotting factors in COVID-19: epidemiological association and prognostic values in different clinical presentations in an Italian cohort. J Clin Med. 2020;9(5):1371.
   Web of Science ®Google Scholar
• Li X, Wang L, Yan S, et al. Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128–132.
   PubMed Web of Science ®Google Scholar
• Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
   Google Scholar
• Chen R, Sang L, Jiang M, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immunol. 2020;146(1):89–100.
   PubMed Web of Science ®Google Scholar
• Fu J, Kong J, Wang W, et al. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a retrospective study in Suzhou China. Thromb Res. 2020;192:3–8.
   PubMed Web of Science ®Google Scholar
• Bi X, Su Z, Yan H, et al. Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count. Platelets. 2020;31(5):674-679.
   PubMed Web of Science ®Google Scholar
• Wang F, Hou H, Luo Y, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10):e137799.
   PubMed Web of Science ®Google Scholar
• Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810.
   PubMed Web of Science ®Google Scholar
• Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19. J Med Virol. 2020;92(7):791–796.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liao W, Wan L, et al. Correlation between relative nasopharyngeal virus RNA load and lymphocyte count disease severity in patients with COVID-19 [published online ahead of print, 2020 Apr 10]. Viral Immunol. 2020. 10.1089/vim.2020.0062.
   Web of Science ®Google Scholar
• Xu D, Zhou F, Sun W, et al. Relationship between serum SARS-CoV-2 nucleic acid(RNAemia) and organ damage in COVID-19 patients: a cohort study. Clin Infect Dis. ciaa1085 (2020).
   Google Scholar
• Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):1–6.
   Web of Science ®Google Scholar
• Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;45(3):230‐32.
   Web of Science ®Google Scholar
• Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection[J]. Front Med. 2020;14(2):185–192.
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687.
   PubMed Web of Science ®Google Scholar
• Zou Y, Guo H, Zhang Y, et al. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. Biosci Trends. 2020;14(4):285–289.
   PubMed Web of Science ®Google Scholar
• Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747–1751. 2020.
   PubMed Web of Science ®Google Scholar
• Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–1098.
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059.
   PubMed Web of Science ®Google Scholar
• Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92(7):797–806.
   PubMed Web of Science ®Google Scholar
• Yang F, Shi S, Zhu J, et al. Clinical characteristics and outcomes of cancer patients with COVID‐19. J Med Virol. 2020;92(10):2067–2073.
   PubMed Web of Science ®Google Scholar
• Yin S, Huang M, Li D, et al. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2020;1–4.
   Google Scholar
• Liu X, Li Z, Liu S, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B. 2020;10(7):1205–1215.
   PubMed Web of Science ®Google Scholar
• Wang K, Zuo P, Liu Y, et al. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. Clinl Infect Dis. 2020;71(16):2079–2088. 19.
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–1741.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–1329.
   PubMed Web of Science ®Google Scholar
• Yan Y, Yang Y, Wang F, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care. 2020;8(1):e001343.
   PubMed Web of Science ®Google Scholar
• Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7)e3319.
   PubMed Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):1–8.
   Web of Science ®Google Scholar
• Yao Q, Wang P, Wang X, et al. Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. Pol Arch Intern Med. 2020;130(5):390–399.
   PubMedGoogle Scholar
• Weng LC, Tang W, Rich SS, et al. A genetic association study of D-dimer levels with 50K SNPs from a candidate gene chip in four ethnic groups. Thromb Res. 2014;134(2):462–467.
   PubMed Web of Science ®Google Scholar
• Smith NL, Huffman JE, Strachan DP, et al. Genetic predictors of fibrin D-dimer levels in healthy adults. Circulation. 2011;123(17):1864–1872.
   PubMed Web of Science ®Google Scholar
• Lange LA, Reiner AP, Carty CL, et al. Common genetic variants associated with plasma fibrin D-dimer concentration in older European- and African-American adults. J Thromb Haemost. 2008;6(4):654–659. Apr.
   PubMed Web of Science ®Google Scholar
• Lutsey PL, Cushman M, Steffen LM, et al. Plasma hemostatic factors and endothelial markers in four racial/ ethnic groups: the MESA study. J Thromb Haemost. 2006;4(12):2629–2635.
   PubMed Web of Science ®Google Scholar
• Takamiya T, Kadowaki T, Zaky WR, et al. The determinants of plasma plasminogen activator inhibitor-1 levels differ for American and Japanese men aged 40–49. Diabetes Res Clin Pract. 2006;72(2):176–182.
   PubMed Web of Science ®Google Scholar
• Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock. JAMA. 2016;315(8):775.
   PubMed Web of Science ®Google Scholar
• Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020;18(5):1020–1022.
   PubMed Web of Science ®Google Scholar
• Thachil J, Wada H, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–1026.
   PubMed Web of Science ®Google Scholar
• Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687–690.
   PubMed Web of Science ®Google Scholar
• Li T. Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of peking union medical college hospital (V2.0). Emerg Microbes Infect. 2020;9(1):582–585.
   PubMed Web of Science ®Google Scholar
• Glas GJ, Van Der Sluijs KF, Schultz MJ, et al. Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome. J Thromb Haemost. 2013;11(1):17–25.
   PubMed Web of Science ®Google Scholar
• Barrett CD, Moore HB, Yaffe MB, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment. J Thromb Haemost. 2020;18(8):2060–2063.
   PubMed Web of Science ®Google Scholar
• Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med. 1976;61(5):585–589.
   PubMed Web of Science ®Google Scholar
• Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British committee for standards in haematology. Br J Haematol. 2009;145(1):24–33.
   PubMed Web of Science ®Google Scholar
• Danzi GB, Loffi M, Galeazzi G, et al. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41(19):1858.
   PubMed Web of Science ®Google Scholar
• Hobl EL, Derhaschnig U, Firbas C, et al. Reversal strategy in antagonizing the P2Y12-inhibitor ticagrelor. Eur J Clin Invest. 2013;43(12):1258–1261.
   PubMed Web of Science ®Google Scholar
• Valeriani E, Squizzato A, Gallo A, et al. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: a systematic review and meta-analysis. J Thromb Haemost. 2020;18(7):1618–1625.
   PubMed Web of Science ®Google Scholar
• Wessling-Resnick M. Crossing the iron gate: why and how transferrin receptors mediate viral entry. Annu Rev Nutr. 2018;38(1):431–458.
   PubMedGoogle Scholar
• Drakesmith H, Prentice A. Viral infection and iron metabolism. Nature Rev Microbiol. 2008;6(7):541–552.
   PubMed Web of Science ®Google Scholar
• Del Vecchio G, Schettini F, Piacente L, et al. Effects of deferiprone on immune status and cytokine pattern in thalassaemia major. Acta Haematol. 2002;108(3):144–149.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang S, Nekhai S, et al. Depriving iron supply to the virus represents a promising adjuvant therapeutic against viral survival. Curr Clinic Microbiol Rep. 2020;7(2):13–19.
   Web of Science ®Google Scholar
• Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372–2374.
   PubMed Web of Science ®Google Scholar
• Shim K, Begum R, Yang C, et al. Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus. World J Diabetes. 2020;11(1):1–12.
   PubMed Web of Science ®Google Scholar
• Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2020;20(5):437–444.
   Google Scholar
• Faienza MF, Acquafredda A, Tesse R, et al. Risk factors for subclinical atherosclerosis in diabetic and obese children. Int J Med Sci. 2020;10(3):338–343.
   Google Scholar
• Passaro A, Addeo A, Von Garnier C, et al. ESMO management and treatment adapted recommendations in the COVID-19 era: lung cancer ESMO open. 2020;5:e000820.
   Google Scholar
• Curigliano G, Banerjee S, Cervantes A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31(10):1320–1335.
   PubMed Web of Science ®Google Scholar
• Terpos E, Engelhardt M, Cook G, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34(8):2000–2011.
   PubMed Web of Science ®Google Scholar
• Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307–1310.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Yu Z, Gou J, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020;222(1):38–43.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470.
   PubMed Web of Science ®Google Scholar
• Rabelo-da-Ponte FD, Silvello D, Scherer JN, et al. Convalescent plasma therapy in patients with severe or life-threatening COVID-19: a metadata analysis. J Infect Dis. 2020;222(9):1575–1578.
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791–4797.
   PubMed Web of Science ®Google Scholar
• Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a matched control study. medRxiv. 2020;05. 20.20102236.
   Google Scholar
• Klein S, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. medRxiv. 2020. 06.26.20139063.
   Google Scholar